In this review we aim to summarize the current knowledge of the patho-physiological aspects of NLRP3 inflammasome activation in the GI tract and the potential therapeutic approaches considered nowadays as alternatives to conventional protocols in patients with inflammatory-driven GI disorders, laying particular emphasis on IBD and cancer. This evidence concerns the gene NLRP3 and cancer.